Favezelimab (MK-4280) is an experimental anti-cancer monoclonal antibody developed by Merck. It is being tested by itself and in a fixed-dose combination with pembrolizumab.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.